Novo Nordisk shifts its recruitment focus to China, expanding operations to meet rising demand for Ozempic and Wegovy in the ...

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

Share on Facebook Share on Twitter Under a new rule the Biden administration proposed on Tuesday, millions of Americans with ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

The Biden administration plans to require Medicare and Medicaid to offer coverage of weight loss medications for people seeking obesity treatment.The new rule, which was proposed by the administration ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

Millions of obese Americans would be eligible to have drugs like Wegovy or Zepbound covered by Medicare or Medicaid under the ...

The White House said it's moving to make the federal health insurance plans pay for anti-obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound for people who are obese, even if they don ...

In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body ...

News of Biden administration's proposal to require Medicare and Medicaid health insurance to cover weight loss drugs could trigger private employers to do the same.

Should employers, patients or insurers cover the $411 billion annual cost for GLP-1 drugs? U.S. healthcare industry grapples with this question as demand grows.